Considering the crucial role of HO-1 in placental development, we set out to study whether the length of fetal GT n repeat could affect maternal preeclampsia risk. Additionally, our aims were to study whether the previously identified association between the long maternal repeat and preeclampsia would manifest as lower serum levels of HO-1 in preeclamptic women and whether the carriers of the long repeat would have decreased levels of HO-1 in the placenta and maternal serum.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Study Participants
The study participants were selected from the FINNPEC (Finnish Genetics of Preeclampsia Consortium) cohort. 16 The study sample for genotyping consisted of cord blood from 1354 neonates (609 preeclamptic and 745 nonpreeclamptic pregnancies). The maternal GT n genotype was available for 1538 women previously genotyped (759 preeclamptic and 779 nonpreeclamptic). 15 There were 451 preeclamptic (320 severe/131 nonsevere preeclampsia; 90 early-onset/361 lateonset preeclampsia) and 672 nonpreeclamptic previously genotyped women whose neonate was genotyped in the present study.
The total number of neonates in the FINNPEC cohort with placental sample and fetal GT n genotype information available was 111, and 36 of the samples were selected for measuring placental HO-1. All the available samples with at least 1 long fetal allele (>33 repeats) were selected (n=9). Furthermore, a comparison group including samples with no long fetal repeats present (n=27) was selected, matching as closely as possible for gestational age, method of delivery, preeclampsia status, and delay from detachment of placenta to sampling. Twenty-four of the samples were from preeclamptic and 12 from nonpreeclamptic pregnancies. Maternal genotype was available for 31 of the samples.
Serum samples were collected from a subcohort of the FINNPEC participants from the Hospital District of Helsinki and Uusimaa. HO-1 serum concentration was measured in 465 first-trimester samples (222 preeclamptic and 243 nonpreeclamptic women) and in 229 third-trimester samples (176 preeclamptic and 53 nonpreeclamptic women). The same samples were used to measure serum concentrations of sEng (soluble endoglin), sFlt-1 (soluble fms-like tyrosine kinase-1; n third-trimester =228) and PlGF (placental growth factor; n first-trimester =464; n third-trimester =228). The first-trimester samples were collected between the 11th and 16th weeks of gestation. Of these samples, 89.9% were collected within the 12th and 13th weeks of gestation and 6.5% in the 14th week. The third-trimester samples were collected between the 24th and 43rd weeks of gestation, mostly close to delivery (16.6% on the day of delivery, 27.1% 1 day before delivery, and further 35.8% between 2 and 7 days before delivery). One sample was collected 2 days after delivery. Four (1.7%) of these late pregnancy samples were collected before the 28th week of gestation, but as majority of the samples were collected within the third trimester, this sample set is denoted as the third-trimester samples (range, 23.9-42.3 weeks; median, 37.1; quartiles 34.0-38.9). Both the first-and third-trimester serum measurements were available for 108 women (83 preeclamptic and 25 nonpreeclamptic).
Clinical definitions of preeclampsia and other end points, genotyping, as well as serum and placenta collection and measurements are described in the Methods section in the online-only Data Supplement.
All study participants and the participating parents of the neonates provided a written informed consent. The coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa approved the study protocol, and the study was performed in accordance with the institutional guidelines.
Statistical Methods
Using the Genetic Power Calculator, 17 a sample size of 599 preeclamptic neonates was estimated to be sufficient to detect relative risks of 1.32 and 1.61 for the short-long (SL) and long-long (LL) genotypes, respectively, with power of 0.80 when α<0.05 assuming preeclampsia prevalence of 5% and a risk allele frequency of 0.65. 15 The Hardy-Weinberg equilibrium was tested with Genepop 4.2. 18, 19 Allelic and genotypic association of the GT n microsatellite with preeclampsia and its subtypes were tested using chi square test and binary logistic regression, respectively. Interaction between the maternal and fetal GT n microsatellite was studied using the -interaction option in logistic regression model in the PLINK software (version 1.07). 20 Interaction was studied in preeclampsia and its subtypes. The effect of fetal genotype on birth weight normalized for sex and gestational age 21 was studied using linear regression. Additive, recessive, and dominant models were used in all genotypic analyses, and all genetic analyses were performed in PLINK (version 1.07).
As the serum measurement data were not normally distributed, nonparametric tests or log 10 -transformed data were applied in the analyses. Effects of the GT n genotype on placental and maternal serum HO-1 concentrations were studied with Mann-Whitney and Kruskal-Wallis tests, respectively. Difference between the firstand third-trimester serum HO-1 levels was tested with Wilcoxon signed-rank test. Difference in ∆HO-1 (the third-trimester serum HO-1 − the first-trimester serum HO-1) between the cases and controls was tested using Mann-Whitney test. Relationships between HO-1 concentration and categorical and continuous variables were studied with Mann-Whitney test and Spearman correlation, respectively. Correlations with maternal serum HO-1 levels were controlled for body mass index (BMI). Stepwise linear regression was performed to further study the effect of the GT n repeat length and several clinical variables on the first-and third-trimester log 10 -transformed HO-1 serum levels. Data on the clinical variables included in the regression model were available for 333 and 173 samples in the first-and third-trimester, respectively. Full list of the variables included in the analyses can be found in Methods section in the online-only Data Supplement. For all statistical tests, a P value <0.05 was considered statistically significant. The statistical analyses were conducted with the IBM SPSS statistics 20 software (IBM, Corp) and R (3.2.2) 22 unless mentioned otherwise, and the data were visualized using ggplot2 (2.1.0) 23 and UpSetR (1.3.0) 24 packages in R (3.2.2).
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Results
Background Characteristics of the Study Population
Maternal and perinatal characteristics of the neonates genotyped are presented in Table S1 in the online-only Data Supplement. The women genotyped for the GT n repeat have been described previously. 15 Background characteristics of the women with the HO-1 placental and serum measurements available are shown in Tables S2 and S3, respectively. Intersection of the samples successfully genotyped or measured for serum HO-1 concentration is presented in Figure 1 .
Allele Frequencies of the Fetal GT n Repeat Polymorphism
Distribution of the fetal GT n repeat lengths ranged from 17 to 42 repeats, the most frequent alleles being 30 (46.5%) and 23 (17.8%; Figure S1 ). We analyzed the association of fetal GT n repeat alleles and genotypes with preeclampsia using the allele categories short (S ≤25 repeats) and long (L >25 repeats). Genotypes of the GT n microsatellite were in Hardy-Weinberg equilibrium in the control group. In addition to the biallelic classes, more subtly defined allele classes S <27, medium (M)=27 to 33, L >33 were used in the analyses exploring the effect of genotype on placental and maternal serum HO-1 concentrations.
Long Fetal GT n Repeat Is Associated With Preeclampsia and Its Severe and Early-Onset Subtypes
The fetal L allele of the GT n repeat and the fetal SL/LL genotypes (additive and dominant models) were associated with mother's preeclampsia when all the samples were included in the analyses (Table) .
When association between the GT n repeat and subtypes of preeclampsia was tested, the SL/LL genotypes (dominant model) were associated with severe preeclampsia. The L allele and the long genotype (additive model) were also associated with early-onset preeclampsia (Table) . The long fetal repeat was not associated with relative birth weight.
We tested interaction between the maternal and fetal GT n genotypes to see whether the fetal genotype would alter the effect of maternal genotype on the risk of preeclampsia and its subtypes but did not find any evidence of such an interaction.
Neonates Carrying the Long GT n Allele (>33 Repeats) Have Decreased Placental HO-1 Levels
To gain functional evidence of the effects of the GT n repeat length on placental HO-1 levels, we compared HO-1 protein concentrations between the placentas of neonates carrying at least 1 long allele (>33 repeats) and the placentas of neonates with no such alleles. HO-1 levels were significantly lower in the long allele group compared with the short allele group, with little overlap between the groups ( Figure 2A) . No difference in HO-1 levels was found between the preeclamptic and nonpreeclamptic placentas. We also tested the relationship between placental HO-1 levels and maternal genotype as well as several phenotypes (maternal age, BMI, maximal blood pressure, proteinuria, parity, method of delivery, fetal sex, birth weight, placental weight, gestational age, and delay between delivery and sampling) but did not observe any connection between HO-1 levels and these variables. However, as our sample size for the latter analyses was relatively modest, we cannot exclude the existence of more subtle effects of these factors on HO-1 levels. We can nevertheless conclude that none of the variables seems to have an effect comparable to that of the fetal genotype. Allele counts and frequencies (%) are presented. Alleles were divided into S (≤25 repeats) and L (>25 repeats) allele classes. χ 2 test and binary logistic regression were applied in the allelic and genotypic association analyses, respectively. CI indicates confidence interval; GTn, guanine-thymine; L, long; OR, odds ratio; and S, short.
Women Carrying the Long GT n Allele (≥33 Repeats) Have Decreased HO-1 Serum Levels During Pregnancy
The effects of maternal and fetal GT n repeat lengths on maternal first-and third-trimester HO-1 serum concentrations were first tested using the genotype groups formed based on 2 allele classes S (≤25) and L (>25). In these analyses, no differences in maternal HO-1 serum concentrations were observed between the maternal or fetal SS, SL, and LL genotype groups.
Next, we studied the effect of maternal and fetal genotypes on serum HO-1 concentrations using more subtly defined genotype classes (SS, SM, SL, MM, ML+LL, S<27, M=27-33, and L>33). 12 In these analyses, serum concentrations differed between the maternal genotype classes ( Figure 2B and 2C) . HO-1 concentration in women with the genotype ML was lower than that in women with the genotype SS, SM, or MM, both in the first and third trimester.
(No maternal LL genotypes with serum sample were available.) In accordance with these results, there was a positive correlation between the first-and third-trimester HO-1 concentrations (ρ=0.282; P=0.003, BMI controlled ρ=0.270; P=0.005; Figure 2D ).
When the effect of similarly defined fetal GT n genotype on maternal serum HO-1 concentration was examined, no differences between the genotype classes were found, showing that the fetal genotype does not significantly affect maternal HO-1 serum concentration. Genotype frequencies in the maternal and fetal samples for which maternal first-or third-trimester HO-1 serum measurements were available are shown in Table S4 .
HO-1 Serum Level Is Not Altered in Preeclampsia
No statistically significant differences were found in the first-or third-trimester HO-1 serum levels between the preeclamptic and nonpreeclamptic women when all the cases were included in the analysis or when subtypes of preeclampsia were analyzed against the controls. There was, however, a modest positive correlation between the first-trimester serum concentrations of HO-1 and the preeclampsia marker sEng (ρ=0.152; P=0.001; Figure S2A) . Also, the third-trimester HO-1 correlated modestly with the sFlt-1/PlGF ratio, which is often increased in preeclamptic women already before the onset of the disease (ρ=0.153; P=0.021; Figure S2B ). The correlation with sEng weakened after controlling for BMI (firsttrimester sEng ρ=0.118; P=0.011 and third-trimester sFlt-1/ PlGF ρ=0.151; P=0.023). After controlling for BMI, there was also a modest negative correlation between the third-trimester PlGF and HO-1 levels (ρ=−0.140; P=0.034).
HO-1 Serum Level Decreases Toward the End of Gestation
HO-1 serum concentration was lower in the third trimester compared with the first trimester (P=3.05×10 −13 ; Figure 3A and 3B). The third-trimester HO-1 level was lower in 82.4% of the total samples, in 81.9% of the cases, and in 84.0% of the controls. There was no statistically significant difference in ∆HO-1 between the cases and controls. The long fetal and maternal guanine-thymine (GT n ) repeats decrease placental and serum HO-1 (heme oxygenase 1) levels, respectively, and the first-and third-trimester serum HO-1 levels correlate positively. A, Neonates possessing at least 1 long (L) allele have decreased HO-1 protein levels in placenta. All the neonates with at least 1 L GT n allele were grouped and compared against the neonates with no long alleles. Genotype classes are based on the allele classes short (S; <27 repeats), medium (M; 27-33 repeats), and L (L; >33 repeats). Statistical significance was tested using Mann-Whitney test. The (B) first-trimester and (C) third-trimester HO-1 protein levels are lower in the maternal ML genotype class compared with the classes SS, SM, and MM. Genotype classes are based on the allele classes S (<27 repeats), M (27-33 repeats), and L (>33 repeats). Statistical significance was tested using KruskalWallis test. An outlier is marked at the top of (B). D, The first-and third-trimester serum HO-1 protein levels correlate statistically significantly (Spearman correlation). PE indicates preeclampsia.
Several Factors Affect HO-1 Serum Concentration
The first-and third-trimester HO-1 levels were lower in the group of obese women compared with the women with BMI <30 kg/m 2 (first-trimester P=6.3×10 ; Figure S3A through 3C). The first-trimester HO-1 concentration was reduced in women with chronic hypertension compared with women with no chronic hypertension diagnosis (P=0.007), and there was a modest negative correlation between the first-trimester HO-1 concentration and maximal systolic (ρ=−0.093; P=0.045) and diastolic (ρ=−0.101; P=0.029) blood pressure measurements. These correlations, however, disappeared after controlling for BMI (systolic ρ=−0.065; P=0.161 and diastolic ρ=−0.065; P=0.163).
The third-trimester HO-1 level correlated positively with age (ρ=0.219; P=0.001 and BMI corrected ρ=0.224; P=0.001; Figure S4A ) and negatively with neonate's birth weight (ρ=−0.159; P=0.016 and BMI corrected ρ=−0.159; P=0.016; Figure S4B ). Both the first-and third-trimester HO-1 levels were lower in women who smoked during pregnancy compared with those who did not smoke (first-trimester P=0.040; third-trimester P=0.032; Figure S4C and S4D) .
Results from the stepwise linear regression analysis are in line with the rest of the analyses (standardized β and P value shown). In the first trimester, significant variables included in the model were BMI (β=−0.237; P=8.0×10 −6 ), the maternal GT n genotype (L>33; ML/LL=1; other genotypes=0; β=−0.171; P=0.001), and type 1 or 2 diabetes mellitus (β=0.147; P=0.005), explaining altogether 10.2% of the variance in the first-trimester HO-1 levels (Table S5) . The results were similar when 4 samples with residuals ≥3 or ≤−3 were excluded (r 2 =0.114). In the third trimester, the maternal GT n genotype (β=−0.323; P=8.0×10 −6 ), smoking during pregnancy (β=−0.178; P=0.013), BMI (β=−0.170; P=0.016), and the third-trimester serum sampling time (gestational week+day; β=−0.138; P=0.049) explained altogether 20.5% of the variance in HO-1 serum levels (Table S5) . When 3 samples with residuals ≥3 or ≤−3 were excluded, the produced model included the maternal GT n genotype (β=−0.266; P=2.3×10 −4 ), smoking during pregnancy (β=−0.231; P=0.002), gestational age at delivery (β=−0.164; P=0.021), and maternal age (β=0.141; P=0.050; model r
Discussion
In the present study, we found an association between preeclampsia and the long fetal GT n repeat located in the promoter of HMOX1. The fetal repeat seems to be associated especially with the severe and early-onset subtypes of the disease. We also showed that the length of the repeat is one of the most significant factors affecting HO-1 levels in placenta and maternal serum during pregnancy, providing support for the causativity of the microsatellite.
To our knowledge, this is the first study to investigate the association of fetal HMOX1 GT n microsatellite polymorphism with preeclampsia and to explore the effect of GT n repeat length on HO-1 levels in placenta and maternal serum during pregnancy. Our sample size for measuring serum HO-1 in preeclampsia case-control sample is larger than in any of the previously published studies. [25] [26] [27] Further strengths of the study include the availability of maternal and neonate DNA, placental and first-and third-trimester serum samples, as well as extensive clinical information. The diagnosis of preeclampsia and all subtypes were ascertained based on medical records and verified independently by a research nurse and a study physician. Limitations of the study include the variance in gestational age at the time of third-trimester serum sampling. As a result, the third-trimester serum samples in the cases and controls were collected at somewhat differing gestational ages. Also, samples were not available for all the mother-fetus pairs. Although many studies have reported strong relationship between HO activity and HO-1 mRNA/protein concentration, 13, 28 it is important to note that the observed increase in protein concentration does not necessarily translate into enhanced enzymatic HO activity. We were not able to assess HO activity in our serum or placental samples due to the extended storage period of the samples. Finally, the P values presented in the article are nominal, and further studies will be needed to validate our results.
It has previously been shown that the long GT n repeat in the HMOX1 promoter reduces transcriptional activity of the gene and leads to reduced level of HO-1 expression. [10] [11] [12] [13] Although the functional mechanism remains unknown, the repeat has been shown to form Z-DNA structure, 29 a conformation that can either activate or repress transcription in a promoter-specific manner. 30 Our study is the first to show the effect of the long GT n repeat in the placenta and during the altered metabolic state of pregnancy. We show that the fetuses possessing at least 1 copy of the long GT n repeat have significantly reduced placental HO-1 levels compared with the fetuses with no long repeats. This observation and the association of the long fetal genotype with preeclampsia together suggest that the long fetal allele might reduce capacity to upregulate placental HO-1 expression during placental development. This is conceptually in line with the long fetal repeat associating with severe and early-onset preeclampsia that often involve placental impairment. This association was not, however, reflected in fetal growth measured by relative birth weight. Furthermore, no difference in placental HO-1 levels was seen between preeclamptic and normal placentas, which might be explained by the phenotypic and pathogenic heterogeneity of preeclampsia and the complexity of HO-1 pathway regulation. The latter observation is in accordance with the findings by Tong et al 31 : this study with the largest sample size thus far found no difference in placental HO-1 mRNA expression between preterm preeclamptic and gestational age-matched controls assessed in the study or in silico microarray analysis. Sufficient HO-1 expression is nevertheless essential for placental development and function. As in our work, previous studies in the human placenta have mostly been performed in tissue collected after birth. However, experimental mouse studies have provided insight into earlier stages of placental development. Crossbreeding heterozygous HO-1 knockout mice leads to smaller litter size, dramatically reduced birth rate of homozygous knockout offspring, reduced placental and fetal growth, morphological changes in placenta, impaired spiral artery remodeling, lower number of uterine natural killer cells, and elevated maternal diastolic blood pressure and plasma sFlt-1 levels. [7] [8] [9] Also, a case report of a child with no functioning HMOX1 gene provides anecdotal evidence, as the child's mother, who had only 1 functioning copy of HMOX1, experienced 2 fetal deaths in her pregnancies. 32 Analogic to the long fetal repeat associating with lower placental HO-1 concentration, we observed reduced serum HO-1 levels during pregnancy in women with the long repeat. Our results also demonstrate that the fetal genotype does not affect maternal serum HO-1 concentration, leading us to conclude that serum HO-1 during pregnancy is mostly of maternal, instead of placental origin. This is in agreement with the previously observed association of maternal long GT n repeat and late-onset, less severe preeclampsia and provides further support for the hypothesis that the long repeat predisposes women to pregnancy-induced endothelial dysfunction via decrease in HO-1 inducibility. The present study also suggests that the genetic predisposition may be exacerbated through other mechanisms (eg, obesity) that reduce HO-1 levels and impair endothelial function during pregnancy, making a pregnant woman less capable of responding to pregnancy-induced metabolic stress. Known connections between cardiometabolic diseases and preeclampsia, [33] [34] [35] as well as between these diseases and the long GT n repeat, 10, 14 are in line with these hypotheses. As we did not find any evidence of interaction between the maternal and fetal genotypes, our results suggest that they might have independent effects and predispose to separate subtypes of the disease, possibly via different mechanisms.
HO-1 is a highly inducible protective enzyme whose expression and activity are elevated by multiple factors such as hypoxia, reactive oxygen species, shear stress, growth factors, and certain drugs such as aspirin and statins. Our study is the first to measure HO-1 serum level at 2 time points of pregnancy, and interestingly, we found that HO-1 level decreases as pregnancy progresses. Our results also demonstrate that HO-1 serum level is negatively related to BMI and smoking during pregnancy and might be negatively related to neonate's birth weight and positively related to age and diabetes mellitus. Previous research is in agreement with some but not all of these observations. In obese children, elevated serum HO-1 levels have been reported. 36 Cigarette smoke has been shown to decrease HO-1 levels in umbilical vein endothelial cells 37 but to induce HO-1 expression in trophoblast cells, 38 suggesting that the effects might be tissue-specific. Oxidative stress produced by smoking results in repression of the Nrf2 (NF-E2-related factor 2)/antioxidant responsive element pathway, a known inducer for HO-1, and might explain reduced serum HO-1 level in smokers. 37 As neonate's birth weight and gestational age at delivery and at the third-trimester serum sampling are correlated, we could not distinguish whether the observed negative relationships between these factors and the third-trimester serum levels are due to decrease in HO-1 expression toward the end of gestation, a response to impaired fetal growth, or both.
Keeping in mind the complex regulation of HO-1 expression and activity, it is hardly surprising that we did not observe any difference in HO-1 serum levels between the preeclamptic cases and controls. This is in agreement with a study by Karthikeyan et al, 39 which found no connection between serum HO-1 level and pregnancy hypertension. However, a few other studies with smaller sample sizes have demonstrated elevated serum HO-1 levels in preeclampsia. [25] [26] [27] Although HO-1 levels were not altered in preeclampsia in the present study, we found a modest positive correlation between the third-trimester HO-1 concentration and the sFlt-1/PlGF ratio, which is higher in preeclampsia already before the onset of the disease.
2,40 HO-1 levels also modestly correlated with sEng levels in the first trimester. These results suggest that HO-1 might be upregulated in response to endothelial dysfunction. Literature on the relationship between HO-1 and antiangiogenic factors is contradictory. It was previously shown that HO-1 inhibits the release of sFlt-1 and sEng in endothelial cells and placental villous explants and that mice lacking HO-1 produce elevated levels of these molecules. 41 However, a recent article concluded that HO-1 does not negatively regulate placental sFlt-1 and sEng secretion in placental or endothelial cells. 31 Our inability to find a connection between serum or placental HO-1 concentrations and preeclampsia does not exclude the relevance of highly-inducible HO-1 in the heterogeneous and multifactorial pathogenesis of this disease. However, our findings suggest that HO-1 has no potential as a diagnostic marker for preeclampsia.
Considering all our observations together, we hypothesize that predisposition to develop preeclampsia may be affected by genetic and environmental mechanisms contributing to reduced maternal or placental HO-1 during pregnancy. A combination of maternal less-inducible allele and pre-existing risk factors, such as obesity, may lead to relative insufficiency of protective pathways and inadequate adaptation to pregnancy-associated metabolic and hemodynamic stress. In contrast, a less-inducible fetal allele could increase the risk for early-onset, severe preeclampsia through insufficient placental tissue-protective mechanisms, impaired vascularization, and endothelial dysfunction.
Perspectives
We have now shown that both the fetal and maternal long GT n repeats in the promoter of HMOX1 are associated with preeclampsia. The fetal long repeat seems to increase the risk for early-onset, severe preeclampsia, whereas the maternal long repeat is associated with milder, late-onset preeclampsia. To our knowledge, this study is among the first to show that the same variant might increase preeclampsia risk both via fetal and maternal genome, likely through independent mechanisms. Our results also demonstrate that the length of the fetal repeat significantly affects levels of placental HO-1, whereas maternal repeat affects HO-1 serum levels during pregnancy. These observations are consistent with fetal and maternal variants associating with different disease subtypes and strengthen the hypothesis of the polymorphism as a causal variant in preeclampsia risk.
